Yuanfang Optoelectronics announced that the company signed an agreement with Hangzhou Heyi Gene Technology Co., Ltd. and its original shareholder Wang Junyi and Hangzhou Tianyi Venture Capital Partnership. The company invested 49.5 million yuan to increase capital and share the shares of Hehe Gene, holding 15 of them. % of shares. Since the beginning of the year, Yuanfang Optoelectronics has started to develop the strategy of “far technology industry platformâ€. Through investment in Mingzhan Network, Hongxiang Technology, Changyi Testing, etc., it has a good layout in the field of industry 4.0 such as 3D printing, infrared imaging and photoelectric detection. Not long ago, Yuanfang Optoelectronics announced the investment in the nuclear magnetic resonance enterprise Newmarket Electronics. This time, the company officially entered the gene sequencing service through investment and 壹 gene, and it was also the company's second-degree overweight in the medical industry. The announcement shows that 壹 gene focuses on genetic technology research and industrialization, based on advanced high-throughput gene sequencing technology, big data processing and cloud computing platform, providing genetic samples for hospitals, universities, research institutes, pharmaceutical companies and the public. Services such as processing, gene sequencing and analysis reports, big data storage and analysis, and gene health management are widely used in disease pathogenesis research, drug development testing, precision medicine (non-invasive prenatal genetic testing, genetic tumor risk prediction, tumor screening). Investigate and personalize medication guidelines, etc.) and genetic health management (personal genome) and other areas of the genetic health industry. At present, the 壹 gene has established cooperative relationships with hundreds of hospitals, research institutes and medical examination institutions nationwide. Yuanfang Optoelectronics pointed out that as of 2011, the global market value of gene sequencing technology has reached 3 billion US dollars. Among them, the gene sequencing technology market is divided into three sub-markets: equipment and consumption laboratory supplies, sequencing services and workflow products. The global market for sequencing services is expected to reach $3.5 billion by 2016. After the investment, Yuanfang Optoelectronics, Wang Junyi and Tianyi Venture Capital held 15%, 76.5% and 8.5% of the shares of Hefei. Among them, Dr. Junjun Wang is the founder of Heyi Gene, who has been engaged in gene sequencing related work during the Ph.D., and has seamlessly entered the well-known gene sequencing organization after his doctoral degree. He has a well-known gene sequencing organization from the grassroots to the executive. With many years of work experience, after years of running-in, the team has accumulated rich technical and management experience in technology and market operations. Under the leadership of Wang Junyi, the 壹 gene has achieved nearly 10 million yuan in sales return for a year, close to the break-even point. At the same time, the company and its original shareholders promised that from June 2015 to May 2018, the company will realize a return of operating income of 165 million yuan. Since the beginning of the year, Yuanfang Optoelectronics has started to develop the strategy of “far-distance technology industry platformâ€. Through investment in Mingzhan Network, Hongxiang Technology, Changyi Testing, etc., it has been rationally deployed in the field of industry 4.0 such as 3D printing, infrared imaging and photoelectric detection. According to previous reports, at the 2014 Annual General Meeting of Shareholders, Chairman Pan Jiangen said that the medical industry will be an important part of the company's future expansion. Not long ago, Yuanfang Optoelectronics announced the investment in NewMay Electronics, which cost 16 million yuan to hold 10% of the latter and officially entered the field of nuclear magnetic resonance. NewMay Electronics promised to achieve a net profit of 35 million yuan in the next three years. Yuanfang Optoelectronics said that the gene sequencing service and the company's main business belong to the same testing technology field, which is in line with the company's established development direction for the medical industry. This investment is an important layout for the company's development of the remote technology industry platform strategy in the direction of medical technology services. It is particularly noteworthy that the remote optoelectronics announcement also covers the cooperation between the company and the 壹 gene. The announcement stated that the company will use its advantages and experience in testing equipment to provide a complete set of testing equipment and equipment for the 壹 gene. If this synergy can be achieved as expected, the company's ability to cut into the field of gene sequencing will be greatly enhanced, the company can not only enter the blue-sea market of gene sequencing detection equipment, but also greatly enhance the company's resource integration capabilities in the gene sequencing industry.
Mucus Extractor is used for obtaining the samples of mucus specimen for surgical or microbiological examination can be used together with Bacterial barrier filter at suction end.After operation the lid can be used to seal the container,very convenient for further testing.
Mucus Extractor,Mucus Mucus Extractor,Sputum Extractor Luck Medical Consumables Co.,LIMITED , https://www.luckmedical.com